产前地塞米松与倍他米松对轻度妊娠期糖尿病血糖控制的影响:一项随机临床试验
在马来西亚一家三级大学医院开展的随机对照试验,纳入饮食控制的妊娠期糖尿病孕妇,比较产前地塞米松(4次6.0mg、间隔12小时)与倍他米松(2次11.4mg、间隔24小时)对给药后连续3天血糖的影响。地塞米松组第2、3天高血糖次数更少,第1至3天血糖中位数更低,其他母婴结局无显著差异。
要点
- 地塞米松组与倍他米松组第1天高血糖次数中位数相似,第2、3天倍他米松组更多。
- 地塞米松组第1至3天血糖中位数均低于倍他米松组。
- 其他母婴结局在两组间无显著差异。
核心结论
- 在采用医学营养治疗的妊娠期糖尿病中,产前地塞米松治疗可优于倍他米松,因为治疗后第2、3天高血糖次数更少,第1至3天血糖中位数更低。
研究设计与样本
- 2021年2月至2023年8月在马来西亚一家三级大学医院开展的随机对照临床试验。
- 研究对象为饮食控制的妊娠期糖尿病并处方产前皮质类固醇的孕妇,随机分为地塞米松4次6.0mg间隔12小时组或倍他米松2次11.4mg间隔24小时组。
主要发现
- 第1天高血糖次数中位数地塞米松组4.0(四分位距2.3-5.0) vs 倍他米松组4.0(四分位距3.5-5.0),P=.168。
- 第2天高血糖次数中位数地塞米松组4.0(四分位距3.0-5.0) vs 倍他米松组5.0(四分位距4.0-5.0),P=.002。
- 第3天高血糖次数中位数地塞米松组1.0(四分位距0.0-2.0) vs 倍他米松组2.0(四分位距1.0-3.0),P<.001。
- 第1天血糖中位数地塞米松组6.3(四分位距5.8-7.0) vs 倍他米松组6.7(四分位距6.3-7.0),P=.016;第2天6.4(6.0-6.9) vs 6.7(6.3-7.2),P=.001;第3天5.2(4.8-5.5) vs 5.7(5.4-6.0),P<.001。
- 第1至3天平均血糖倍他米松组6.6 mmol/L(97.5%置信区间6.4-6.7) vs 地塞米松组6.2 mmol/L(97.5%置信区间6.0-6.4),平均差-0.374(97.5%置信区间-0.521至-0.226),P<.001;其他母婴结局两组无显著差异。
关键数值与推荐
- 高血糖定义为空腹或餐前血糖≥5.3 mmol/L(≤95 mg/dL)或餐后2小时血糖≥6.7 mmol/L(120 mg/dL)。
- 自我监测毛细血管血糖为每24小时6个时间点:3顿主餐前2小时和餐后2小时。
临床怎么用
- 作者认为在采用医学营养治疗的妊娠期糖尿病中,产前地塞米松治疗可优于倍他米松。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preterm birth and gestational diabetes mellitus are common complications of pregnancy. A widely known side effect of antenatal corticosteroids on fetal maturity in preterm births is maternal hyperglycemia. The choice of antenatal corticosteroid regimens between dexamethasone and betamethasone highly depends on local availability and cost, as current but inconclusive evidence shows similar neonatal outcomes for both regimes. OBJECTIVE: This study aimed to compare four 6.0-mg doses of antenatal dexamethasone administered 12 hours apart vs two 11.4-mg doses of antenatal betamethasone administered 24 hours apart in medical nutrition therapy-controlled gestational diabetes mellitus cases on maternal glycemic response for up to 3 consecutive days after administration. STUDY DESIGN: This was a randomized controlled clinical trial conducted between February 2021 and August 2023 at a tertiary university hospital in Malaysia. Pregnant participants with diet-controlled gestational diabetes mellitus and prescribed antenatal corticosteroid were randomized to either four 6.0-mg doses of dexamethasone administered 12 hours apart or two 11.4-mg doses of betamethasone administered 24 hours apart. Self-monitoring of capillary blood glucose level (6 points per 24 hours: 2 hours before and after a meal for the 3 main meals) was started after the first dose of allocated antenatal corticosteroid. Hyperglycemia was defined as a fasting or premeal glucose level of ≥5.3 mmol/L (≤95 mg/dL) or a 2-hour postmeal glucose level of ≥6.7 mmol/L (120 mg/dL). The primary outcomes were number of hyperglycemic episodes within the first and second 24 hours after antenatal corticosteroid administration. Analyses were performed using the t test, Mann-Whitney U test, and chi-square test, as appropriate. RESULTS: The median hyperglycemic episodes were similar between the dexamethasone group and the betamethasone group: 4.0 (interquartile range, 2.3-5.0) vs 4.0 (interquartile range, 3.5-5.0), respectively, on day 1 (P=.168), 4.0 (interquartile range, 3.0-5.0) vs 5.0 (interquartile range, 4.0-5.0), respectively, on day 2 (P=.002), and 1.0 (interquartile range, 0.0-2.0) vs 2.0 (interquartile range, 1.0-3.0), respectively, on day 3 (P<.001). In addition, the median blood glucose levels were significantly lower in the dexamethasone group than in the betamethasone group on days 1, 2, and 3 (day 1: 6.3 [interquartile range, 5.8-7.0] vs 6.7 [interquartile range, 6.3-7.0], respectively; P=.016; day 2: 6.4 [interquartile range, 6.0-6.9] vs 6.7 [interquartile range, 6.3-7.2], respectively; P=.001; day 3: 5.2 [interquartile range, 4.8-5.5] vs 5.7 [interquartile range, 5.4-6.0], respectively; P<.001). The mean blood glucose levels were higher in the betamethasone group than in the dexamethasone group on day 1 to 3 (6.2 mmol/L [97.5% confidence interval, 6.0-6.4] vs 6.6 mmol/L [97.5% confidence interval, 6.4-6.7], respectively; mean difference, -0.374 [97.5% confidence interval, -0.521 to -0.226], respectively; P<.001). Other maternal and neonatal outcomes were not significantly different between the groups. CONCLUSION: In gestational diabetes mellitus on medical nutrition therapy, dexamethasone antenatal corticosteroid therapy could be preferred over betamethasone, as hyperglycemic episodes on days 2 and 3 after treatments were fewer and the median blood glucose levels were lower on day 1 to day 3. El resumen está disponible en Español al final del artículo.
引用
- Shareef FS, Hong J, Saaid R, et al. Antenatal dexamethasone vs betamethasone on glycemic control in mild gestational diabetes: a randomized clinical trial. Am J Obstet Gynecol MFM. 2025. PMID: 40473019. doi:10.1016/j.ajogmf.2025.101715
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。